10-Q: BioSig Reports Q2 Loss Amid Streamex Acquisition

BioSig Technologies reports a significant increase in net loss and working capital deficit for Q2 2025, driven by the Streamex acquisition and related expenses, while securing substantial new financing.

Summary

• Net loss attributable to common shareholders for the three months ended June 30, 2025, was $20.37 million, compared to $3.92 million for the same period in 2024.
• For the six months ended June 30, 2025, net loss attributable to common shareholders was $23.19 million, up from $7.46 million in 2024.
• Revenue for both the three and six months ended June 30, 2025, was $0, down from $13,000 and $27,000 respectively in 2024.
• General and administrative expenses surged by 303% to $19.79 million for the three months ended June 30, 2025, primarily due to $12.1 million in stock-based compensation and $6.0 million in finders fees related to the Streamex acquisition.
• Research and development expenses decreased by 94% to $19,000 for the three months ended June 30, 2025, reflecting a strategic shift in resource allocation towards the Streamex acquisition.
• The company completed the acquisition of Streamex Exchange Corporation on May 28, 2025, a pre-revenue software development company focused on digital tools for commodity trading and finance, including blockchain-based platforms for real-world asset tokenization.
• Total assets increased significantly to $109.72 million as of June 30, 2025, from $842,000 at December 31, 2024, largely due to $58.69 million in goodwill and $47.92 million in intangible assets from the Streamex acquisition.
• Total liabilities rose to $113.20 million as of June 30, 2025, from $2.26 million at December 31, 2024, primarily due to a $105.50 million derivative liability associated with the Exchangeable Shares issued in the Streamex acquisition.
• The company reported a working capital deficit of $110.00 million as of June 30, 2025.
• Cash and cash equivalents increased to $2.82 million as of June 30, 2025, from $142,000 at December 31, 2024, with $2.39 million cash used in operating activities for the six months ended June 30, 2025, offset by $4.70 million from financing activities.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by zero revenue, escalating losses, a massive working capital deficit, and an explicit going concern warning. While new financing has been secured, it is highly dilutive and the strategic pivot to a pre-revenue blockchain business introduces significant new risks and uncertainties. The identified material weaknesses in internal controls further compound the negative outlook.

Positives

• Successfully completed the acquisition of Streamex Exchange Corporation, expanding into digital commodity trading and blockchain-based financial technologies.
• Secured significant financing commitments post-period, including a Senior Secured Convertible Debenture Purchase Agreement for up to $100 million and a Standby Equity Purchase Agreement for up to $1 billion, addressing immediate liquidity concerns.
• Completed a public offering on August 15, 2025, raising approximately $13.62 million in net proceeds, further bolstering liquidity.
• Cash balance increased to $2.82 million as of June 30, 2025, from $142,000 at December 31, 2024.

Negatives

• Reported a substantial net loss of $23.19 million for the six months ended June 30, 2025, a significant increase from $7.46 million in the prior year period.
• Generated no revenue for the three and six months ended June 30, 2025, indicating a lack of commercial sales from its core medical device business and the pre-revenue status of the acquired Streamex business.
• Experienced a dramatic increase in working capital deficit to $110.00 million as of June 30, 2025, primarily due to the recognition of a large derivative liability.
• General and administrative expenses soared due to acquisition-related costs, including significant stock-based compensation and finders fees.
• The company has substantial doubt about its ability to continue as a going concern, requiring additional financing to fund future operations.
• Identified material weaknesses in internal control over financial reporting, including inadequate identification/reporting of stock-based compensation, ineffective review processes, inadequate segregation of duties, and ineffective review controls over business combinations and financial instruments.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses, negative cash flows from operations, and insufficient cash to fund operations for the next twelve months.
• The Streamex business is in the development stage and pre-revenue, requiring additional costs for platform development, regulatory compliance, and strategic partnerships before generating revenue.
• The Series C Preferred Stock includes triggering events that may require redemption, potentially creating a significant liquidity obligation that the company may not be able to satisfy.
• Future capital requirements are substantial and dependent on the success of R&D programs, regulatory approvals, market acceptance, and the scaling of the Streamex platform, with no assurance of obtaining necessary funding on acceptable terms.
• Future financing, including the recently announced debentures and SEPA, could result in significant dilution to existing shareholders or the issuance of securities with senior rights.
• The valuation of Exchangeable Shares (derivative liability) is highly sensitive to assumptions regarding Streamex's future performance, regulatory milestones, and shareholder approval, which are inherently uncertain.
• If shareholder approval for the Streamex Exchangeable Shares is not obtained by November 28, 2025, the exchange ratio will adjust from 1.0 to 1.25, increasing the number of shares issuable and potentially requiring a material upward revision to the derivative liability.
• Material weaknesses in internal control over financial reporting could negatively impact the company's ability to accurately report financial results in a timely manner and may lead to regulatory actions or loss of investor confidence.

Future Outlook

The company expects to continue incurring operating losses and negative cash flows until its products achieve sustained commercial success. The recently acquired Streamex business is in the development stage and is expected to incur additional costs related to platform development, regulatory compliance, and strategic partnerships before revenue-generating activities commence. The company is actively exploring various funding sources, including public/private equity offerings, strategic partnerships, government grants, and debt financing, and has implemented cost-saving measures. Future capital requirements will depend on the progress of R&D programs, regulatory approvals, intellectual property protection, market acceptance, and the scaling of Streamex's platform. The company intends to seek shareholder approval for matters related to the Streamex acquisition, including increasing authorized common stock and classifying the board of directors.

Management Comments

• "We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, such as the progress of our research and development and commercialization efforts, the timing and outcome of future regulatory submissions and uncertainty around the current pandemic."
• "These reductions [in R&D expenses] reflect a strategic shift in resource allocation during the quarter, as the Company prioritized efforts toward closing the Streamex acquisition."
• "Our ability to continue as a going concern is dependent on securing additional financing."
• "We have implemented cost-saving measures to reduce our operating expenses, including reductions in executive compensation, workforce, and reliance on external consultants."
• "Management believes it is probable that shareholder approval will be obtained within the specified period, and therefore, the contingency is not considered to represent a currently estimable obligation under ASC 805."

Industry Context

BioSig Technologies, traditionally a medical device company focused on electrophysiology with its PURE EP Platform, has made a significant strategic pivot by acquiring Streamex Exchange Corporation. This acquisition propels BioSig into the nascent but rapidly evolving digital asset and blockchain industry, specifically targeting the tokenization of real-world assets (RWAs) like gold. This move diversifies the company's focus beyond its core medical technology, which is shifting from commercial hardware to software algorithms for cardiac ablation. The RWA tokenization market is gaining traction, aiming to bring traditional assets onto blockchain for increased liquidity and transparency. However, this new venture is pre-revenue and highly speculative, contrasting sharply with the established, albeit slow-to-commercialize, medical device sector. The success of this pivot will depend on the company's ability to navigate complex regulatory landscapes, build robust blockchain infrastructure, and establish strategic partnerships in a competitive and evolving digital finance space.

Comparison to Industry Standards

• The company's lack of revenue from its PURE EP Platform indicates a struggle to achieve commercial success in the medical device market, contrasting with more established players like Boston Scientific or Johnson & Johnson, which have robust revenue streams from their electrophysiology portfolios.
• The acquisition of Streamex, a pre-revenue blockchain company, positions BioSig in a highly speculative and emerging market. Direct comparisons are difficult due to the early stage of RWA tokenization, but successful projects in this space, such as Paxos Gold (PAXG) or Tether Gold (XAUT), have demonstrated market acceptance for tokenized gold, albeit with different business models focused on stablecoin-like offerings rather than a full trading platform.
• The significant increase in G&A expenses due to acquisition-related stock-based compensation and finders fees is common in M&A, but the magnitude relative to the company's zero revenue and overall financial position is a concern, suggesting a high cost of strategic transformation.
• The company's reliance on highly dilutive equity and debt financing, such as the SEPA and convertible debentures, is typical for early-stage or distressed companies in both biotech and emerging tech sectors, but it contrasts with financially stable companies that can fund growth through retained earnings or less dilutive debt.

Management Changes

Corporate Governance

Legal Proceedings

• A litigation threat received on February 22, 2024, seeking approximately $1.44 million for alleged unlawful actions, was settled on March 24, 2025, with an accrual of $494,000 as of June 30, 2025.

Related Party Transactions

• Accounts payable and accrued expenses include $466,000 due to related parties as of June 30, 2025, compared to $19,000 at December 31, 2024.
• An amount of $11,000 is due from Henry McPhie, the new Chief Executive Officer and Board of Directors, as of June 30, 2025.
• Issued 235,000 shares of common stock with a fair value of $0.95 million to Mr. Groenewald, the Interim Chief Financial Officer, during the six months ended June 30, 2025.
• Issued 2,198,345 shares of common stock with an aggregate fair value of $5.9 million to Mr. Amato, the former Chief Executive Officer, primarily in connection with his resignation and the acceleration of equity awards due to the Streamex acquisition.

Stakeholder Impact

• **Shareholders**: Face significant dilution from recent and planned capital raises (ATM, debentures, SEPA, public offering) and the issuance of shares for the Streamex acquisition. The substantial net losses and going concern warning indicate a high risk to investment value. Potential for further dilution if shareholder approval for increased authorized shares is obtained.
• **Employees**: Impacted by the strategic shift in R&D focus and changes in executive leadership. Stock-based compensation remains a significant component of compensation, but the overall financial instability could affect job security and morale.
• **Customers (PURE EP)**: Minimal revenue from the PURE EP Platform suggests limited market penetration or adoption, potentially impacting the long-term viability of this product line.
• **Creditors**: The large working capital deficit and going concern warning indicate increased credit risk. The new secured convertible debentures provide a senior claim on assets, potentially impacting other creditors.
• **Streamex Shareholders (now BioSig Exchangeable Share Holders)**: Their investment is tied to the success of the new blockchain venture and is subject to shareholder approval for full conversion rights, with a potential adjustment to the exchange ratio if approval is not obtained by November 28, 2025.

Next Steps

• Seek shareholder approval for matters outlined in the Share Purchase Agreement, including the issuance of common stock exchangeable for Exchangeable Shares, approval of a New Incentive Plan, and an amendment to increase authorized common stock to 500 million shares.
• Seek shareholder approval to classify the board of directors into three staggered classes.
• File a registration statement with the SEC to register the issuance and sale of shares under the Equity Line of Credit and the SEPA.
• Continue platform development, regulatory compliance, and strategic partnerships for the Streamex business, with revenue-generating activities expected upon the launch of its tokenized gold financing product.
• Continue research and development of proprietary software algorithms for the PURE EP Platform, focusing on cardiac tissue characteristics and ablation mechanisms.
• Implement remediation plans to address identified material weaknesses in internal control over financial reporting, including adding sufficient staff and oversight supervision controls.

Key Dates

Recommendation

The company is in a precarious financial position, marked by zero revenue, a substantial increase in net losses, and a severe working capital deficit, leading to an explicit 'going concern' warning. While recent and planned capital raises provide some liquidity, they are highly dilutive and underscore the company's inability to generate sufficient cash from operations. The strategic pivot into the pre-revenue blockchain/RWA space, while potentially high-growth, introduces significant speculative risk and has already incurred substantial acquisition-related costs and a large derivative liability. The identified material weaknesses in internal controls further erode investor confidence. Given the high financial risk, lack of current revenue, and the speculative nature of its new venture, a seasoned investor would likely recommend a strong sell to mitigate further potential losses.

Keywords

Medical Device, Electrophysiology, PURE EP Platform, Blockchain, Real-World Assets, RWA Tokenization, Commodity Trading, Digital Finance, Going Concern, SEC Filing, 10-Q, Biotech, Fintech